Evidence map›Paper›PMID 24287500›Full record

Trial reportJAMA ophthalmology2014

Prospective study of common variants in CX3CR1 and risk of macular degeneration: pooled analysis from 5 long-term studies.

Debra A Schaumberg, Lynda Rose, Margaret M DeAngelis, Richard D Semba, Gregory S Hageman, Daniel I Chasman

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. The CX3CL1-CX3CR1 axis in HIV-associated inflammation and cardiometabolic disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Review
  2. Article
  3. Article
  4. Association betweenMolecular biology research communications · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Inflammation and its role in age-related macular degeneration.Cellular and molecular life sciences : CMLS · 2016
    Review
  12. Article
  13. Inflammatory Mechanisms of Age-related Macular Degeneration.International ophthalmology clinics · 2015
    Review
  14. Article
  15. CX3CR1 polymorphisms and the risk of age-related macular degeneration.International journal of clinical and experimental pathology · 2015
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Debra A SchaumbergDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2The Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts3Department.
Lynda RoseDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Margaret M DeAngelisThe John A. Moran Eye Center, University of Utah, Salt Lake City.
Richard D SembaWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Gregory S HagemanThe John A. Moran Eye Center, University of Utah, Salt Lake City.
Daniel I ChasmanDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Harvard University · USUniversity of Utah · USBrigham and Women's Hospital · USJohns Hopkins University · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
Dietary Etiology of Heart DiseaseR01HL035464 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ERIC B RIMM, Qi Sun · 1986 to 2026
$13.6M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
BIOCHEMICAL MARKERS IN THE NURSES HEALTH STUDY COHORTU01CA049449 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI HANKINSON, SUSAN E · 1995 to 2013
$5.4M
SIBLING STUDY OF AGE-RELATED MACULAR DEGENERATIONR01EY014458 · NEI · UNIVERSITY OF UTAH · PI DEANGELIS, MARGARET M · 2003 to 2010
$4.2M
TRIAL OF ANTIOXIDANT THERAPY OF CVD IN WOMENR01HL046959 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MANSON, JOANN ELISABETH · 1993 to 2005
$3.6M
Genetic Epidemiology of Age-Related Macular DegenerationR01EY017362 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHAUMBERG, DEBRA A · 2007 to 2011
$2.9M
PROSPECTIVE STUDY OF RISK FACTORS FOR EYE DISEASER01EY009611 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E. · 1995 to 2004
$2.2M
TRIAL OF VITAMIN E, BETA-CAROTENE &ASPRIN IN WOMENR01HL043851 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1991 to 2000
$1.6M
Molecular Risk Factors for Age-Related MaculopathyR01EY013834 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHAUMBERG, DEBRA A · 2002 to 2004
$945k
NCI NIH HHS CA40360NCI NIH HHS CA47988NCI NIH HHS CA49449NCI NIH HHS CA87969NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA047988NCI NIH HHS R01 CA049449NCI NIH HHS U01 CA049449NEI NIH HHS EY009611NEI NIH HHS EY013834NEI NIH HHS EY014458NEI NIH HHS EY017362NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY009611NEI NIH HHS R01 EY013834NEI NIH HHS R01 EY014458NEI NIH HHS R01 EY017362NHLBI NIH HHS HL35464NHLBI NIH HHS HL43851NHLBI NIH HHS HL46959NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NHLBI NIH HHS R01 HL035464NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL046959
6 · The paper itself

Abstract

importanceThe CX3CR1 gene is implicated as a candidate gene for age-related macular degeneration (AMD) through several lines of evidence. There is uncertainty, however, as to whether common genetic variants in CX3CR1 alter risk of AMD, since prior studies have been inconsistent and mostly limited to evaluation of 2 nonsynonymous variants, T280M (rs3732378) and V249I (rs3732379).

objectiveTo determine if common variants in CX3CR1 predict future risk of AMD. DESIGN, SETTING, AND

participantsProspective nested case-control study within 5 large study populations with long-term follow-up. We measured genotypes for T280M, V249I, and 13 other common single-nucleotide polymorphisms (SNPs) of the CX3CR1 gene among people who developed AMD (n = 1110, including 369 with neovascular AMD) and 2532 age- and sex-matched controls. MAIN OUTCOMES AND MEASURES: We determined the incidence rate ratios (RR) and 95% CIs for incidence of AMD for each variant and examined interactions with other AMD-associated variants and modifiable risk factors.

resultsIn additive genetic models, we identified nonsignificant associations with AMD for T280M (RR, 0.87; P = .07) and 3 other SNPs, rs2853707 (RR, 0.88; P = .07), rs12636547 (RR, 0.85; P = .10), and rs1877563 (RR, 0.84; P = .06), 1 of which, rs2853707, is positioned in the CX3CR1 promoter region and was associated with neovascular AMD (RR, 0.75; P = .03). We observed that a recessive model was a better fit to the data for some SNPs, with associations between rs11715522 and AMD (RR, 1.27; P = .03) and between rs2669845 (RR, 3.10; P = .04), rs2853707 (RR, 0.48; P = .050), and rs9868689 (RR, 0.31; P = .02) and neovascular AMD. Moreover, in exploratory analyses, we identified a number of possible interactions including between V249I and rs2669845 and dietary intake of ω-3 fatty acids (P = .004 and P = .009, respectively) for AMD; between rs2669845 and obesity (P = .03) for neovascular AMD; between T280M and complement component 3 (C3) R102G for AMD (P = .03); between rs2669845 and Y402H in complement factor H for AMD (P = .04); and between rs2669845, rs2853707, and V249I and C3 R102G for neovascular AMD (P = .008; .04; and .002, respectively). CONCLUSIONS AND RELEVANCE: This study failed to identify significant associations between common CX3CR1 variants and AMD after considering the number of SNPs analyzed and multiple comparisons. However, we observed evidence consistent with recessive modes of association and that an effect of CX3CR1 variants may depend on other factors including dietary intake of ω-3 fatty acids, obesity, and genotypes at CFH Y402H and C3 R102G. If replicated in other populations, these findings would support a role for CX3CR1 in AMD but also suggest that its role may involve mechanisms that are independent of the T280M/V249I variations.

Indexed as

Polymorphism, Single NucleotideAllelesCase-Control StudiesChromosomes, Human, Pair 3Complement C3Complement Factor HCX3C Chemokine Receptor 1Dietary Fats, UnsaturatedDouble-Blind MethodFatty Acids, Omega-3FemaleFollow-Up StudiesGene-Environment InteractionGenotypeHealth PersonnelHumansARMS2 protein, humanCFH protein, humanComplement C3Complement Factor HCX3C Chemokine Receptor 1CX3CR1 protein, humanDietary Fats, UnsaturatedFatty Acids, Omega-3ProteinsReceptors, Chemokine

Identifiers

PMID24287500
PMCPMC4170669
OpenAlexW2087293138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.